查看文章

To develop recommendations concerning the management of male breast cancer.

ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process.

Twenty-six descriptive reports or observational studies met eligibility criteria and formed the evidentiary basis for the recommendations.

Many of the management approaches used for men with breast cancer are like those used for women. Men with hormone receptor–positive breast cancer who are candidates for adjuvant endocrine therapy should be offered tamoxifen for an initial duration of five years; those with a contraindication to tamoxifen may be offered a gonadotropin-releasing hormone agonist/antagonist plus aromatase inhibitor. Men who have completed five years of tamoxifen, have tolerated therapy, and still have a high risk of recurrence may …